{
  "schema_version": "kingdom.geometry.case/1.0",
  "id": "geometry.ritonavir-disappearing-polymorph",
  "slug": "ritonavir",
  "aliases": [
    "ritonavir-disappearing-polymorph",
    "polymorph"
  ],
  "title": {
    "en": "Ritonavir and the \"disappearing polymorph\""
  },
  "essence": {
    "en": "A state can remain physically possible while history makes the old route to it unreliable."
  },
  "scope": {
    "use": {
      "en": "An educational case about crystal polymorphism, reachability, seeding, and path dependence."
    },
    "not": [
      "medical advice",
      "a pharmaceutical manufacturing procedure",
      "evidence that crystals think or that agent systems obey crystal physics"
    ]
  },
  "languages": [
    "en"
  ],
  "registers": [
    "plain",
    "systems",
    "technical"
  ],
  "register_intros": {
    "plain": {
      "en": "Same pieces, two structures"
    },
    "systems": {
      "en": "A landscape with memory in its surroundings"
    },
    "technical": {
      "en": "Conformational polymorphism, nucleation, and process history"
    }
  },
  "distinctions": [
    {
      "id": "four-separations",
      "text": {
        "en": "existence != reachability != prevalence != acceptability"
      },
      "explanation": {
        "en": "A form may exist, be hard to reach, be uncommon or dominant, and be acceptable or unacceptable for a particular use. Those are four different questions."
      }
    },
    {
      "id": "agent-separations",
      "text": {
        "en": "capability != elicitation != default behavior != authorization or truth"
      },
      "explanation": {
        "en": "This is a systems analogy, not a physical equivalence: what a model can produce, what a prompt elicits, what appears by default, and what is authorized or true must be assessed separately."
      }
    }
  ],
  "state_model": {
    "equation": "state = molecular conformation + lattice + solvent + temperature + supersaturation + seeds/surfaces + impurities + time + mechanical history",
    "diagram": "conditional access map (schematic; not to scale)\n\nsolution/process state --lower initial barrier--------> Form I basin\n                       \\--higher unseeded barrier------> Form II basin*\n                       \\--Form-II seed lowers barrier--> Form II basin*\n\nForm I --dissolution--> solution --Form-II growth----> Form II\n\n*Deeper/more stable and less soluble in the reported context.",
    "diagram_note": {
      "en": "The real landscape is multidimensional and changes with conditions. The labels distinguish relative thermodynamic stability from access difficulty; the arrows are possible routes, not a single reaction coordinate. A seed changes a path or barrier, not necessarily the final basin depth."
    },
    "states": [
      {
        "id": "solution",
        "label": {
          "en": "ritonavir in solution"
        }
      },
      {
        "id": "form_i",
        "label": {
          "en": "Form I: initially accessible, metastable crystal"
        }
      },
      {
        "id": "form_ii",
        "label": {
          "en": "Form II: harder to nucleate, more stable and less soluble in the reported context"
        }
      }
    ],
    "transitions": [
      {
        "from": "solution",
        "to": "form_i",
        "access": "easier_unseeded_in_initial_process"
      },
      {
        "from": "solution",
        "to": "form_ii",
        "access": "difficult_unseeded_in_initial_process"
      },
      {
        "from": "solution",
        "to": "form_ii",
        "modifier": "form_ii_seed",
        "effect": "nucleation_barrier_reduced_when_growth_conditions_allow"
      },
      {
        "from": "form_i",
        "to": "form_ii",
        "via": "dissolution_then_form_ii_growth",
        "note": "Do not assume a direct solid-state flip."
      }
    ]
  },
  "stages": [
    {
      "id": "identity",
      "order": 1,
      "title": {
        "en": "Same molecule, different solid"
      },
      "content": {
        "plain": {
          "en": "Form I and Form II contain the same ritonavir compound. The flexible molecules bend and pack differently, like identical pieces assembled into two different walls. This is crystal polymorphism, not a mutation of the drug molecule and not genetic polymorphism."
        },
        "systems": {
          "en": "First separate identity from arrangement. Components can remain the same while their collective configuration changes the behavior of the whole."
        },
        "technical": {
          "en": "Ritonavir Forms I and II are conformational polymorphs: the crystal structures contain different molecular conformations and lattices while retaining the same chemical identity."
        }
      },
      "claim_ids": {
        "plain": [
          "c01",
          "c05",
          "c14"
        ],
        "systems": [
          "c01",
          "c05",
          "c14"
        ],
        "technical": [
          "c01",
          "c05"
        ]
      }
    },
    {
      "id": "landscape",
      "order": 2,
      "title": {
        "en": "Easy to reach is not the same as most stable"
      },
      "content": {
        "plain": {
          "en": "Wall I was easier to start. Wall II needed a rarer starting arrangement, but once built its network held together more strongly and dissolved less readily."
        },
        "systems": {
          "en": "A shallow, easy entrance can dominate early experience while a deeper basin remains unseen behind a high bootstrap cost. Search history does not enumerate every possible state."
        },
        "technical": {
          "en": "In Abbott's reported process context, Form I was the kinetically accessible metastable form. Form II had lower solubility and greater bulk thermodynamic stability; its different molecular conformation participated in stronger intermolecular packing."
        }
      },
      "claim_ids": {
        "plain": [
          "c02",
          "c04",
          "c05",
          "c14"
        ],
        "systems": [
          "c02",
          "c04",
          "c05",
          "c14"
        ],
        "technical": [
          "c02",
          "c04",
          "c05"
        ]
      }
    },
    {
      "id": "rare_event",
      "order": 3,
      "title": {
        "en": "A rare route opened"
      },
      "content": {
        "plain": {
          "en": "Ritonavir was an HIV medicine. In 1998, some semisolid capsule lots failed dissolution tests after the much less soluble Form II appeared, threatening supply and forcing urgent reformulation. Once a Form-II nucleus existed, it supplied a starting pattern when the solution could support growth."
        },
        "systems": {
          "en": "The important event is a transition across a barrier. It can be rare without being impossible. A template, fluctuation, interface, or impurity can alter the chance of crossing."
        },
        "technical": {
          "en": "Form II was detected after capsule dissolution failures. The formulation was reported as highly supersaturated relative to Form II. Abbott proposed a cyclic-carbamate degradation product as a possible heterogeneous nucleation template, but the historical trigger was not established."
        }
      },
      "claim_ids": {
        "plain": [
          "c03",
          "c06",
          "c12",
          "c15",
          "c17"
        ],
        "systems": [
          "c03",
          "c06",
          "c12",
          "c15"
        ],
        "technical": [
          "c03",
          "c06",
          "c12",
          "c17"
        ]
      }
    },
    {
      "id": "seed_memory",
      "order": 4,
      "title": {
        "en": "The environment acquired physical memory"
      },
      "content": {
        "plain": {
          "en": "When the surrounding solution can support growth, a fragment of Wall II works like a jig. It gives incoming pieces a matching surface on which to continue the same pattern."
        },
        "systems": {
          "en": "The written recipe was no longer the whole initial state. Seed-bearing material, surfaces, and equipment carried history forward. Memory here is physical persistence, not awareness."
        },
        "technical": {
          "en": "Form-II seed surfaces reduced the nucleation barrier under suitable supersaturation. Abbott's specially designed assay detected Form II at 1 ppm; that sensitivity is not a universal transformation threshold."
        }
      },
      "claim_ids": {
        "plain": [
          "c07",
          "c10",
          "c11"
        ],
        "systems": [
          "c07",
          "c10",
          "c11"
        ],
        "technical": [
          "c07",
          "c10"
        ]
      }
    },
    {
      "id": "feedback",
      "order": 5,
      "title": {
        "en": "Growth made future growth easier"
      },
      "content": {
        "plain": {
          "en": "Under growth-supporting conditions, one Form II crystal could grow into more crystal and more fragments. More fragments meant more places for Form II to start in later batches."
        },
        "systems": {
          "en": "The loop is positive feedback: nucleus -> matching growth surface -> more material -> more seeds -> easier recurrence. No molecule decides; thermodynamics, kinetics, fluctuations, surfaces, and process choices shape probabilities."
        },
        "technical": {
          "en": "Once nucleated, Form II could grow from a solution supersaturated with respect to it. Spread of seeds through bulk-drug and formulation areas changed later crystallization conditions even when the nominal recipe looked unchanged."
        }
      },
      "claim_ids": {
        "plain": [
          "c06",
          "c07",
          "c10",
          "c11"
        ],
        "systems": [
          "c06",
          "c07",
          "c10",
          "c11"
        ],
        "technical": [
          "c06",
          "c07",
          "c10"
        ]
      }
    },
    {
      "id": "hysteresis",
      "order": 6,
      "title": {
        "en": "What actually 'disappeared'"
      },
      "content": {
        "plain": {
          "en": "Form I did not cease to exist. The old routine stopped reaching it reliably after Form II and its seeds entered the process. The route disappeared from dependable practice; the state did not vanish from nature."
        },
        "systems": {
          "en": "This is path dependence, sometimes described as hysteresis: the same visible settings can produce a different outcome because hidden historical state has changed."
        },
        "technical": {
          "en": "'Disappearing polymorph' is an operational and historical description. Controlled crystallization and later alternative routes recovered Form I, demonstrating the difference between physical possibility and routine reproducibility."
        }
      },
      "claim_ids": {
        "plain": [
          "c08",
          "c13",
          "c15"
        ],
        "systems": [
          "c08",
          "c13",
          "c15"
        ],
        "technical": [
          "c08",
          "c13"
        ]
      }
    },
    {
      "id": "control",
      "order": 7,
      "title": {
        "en": "Change the route and test the relevant state"
      },
      "content": {
        "plain": {
          "en": "The response was not to argue with the crystal. It was to detect the form, control the environment, and redesign the route or formulation around the property that mattered."
        },
        "systems": {
          "en": "When a basin becomes self-reinforcing, commands alone do little. Change interfaces, starting state, feedback, tests, and fallback routes. Preserve provenance so success is not confused with exhaustive search."
        },
        "technical": {
          "en": "The case motivates form characterization and controls linked to performance, such as dissolution, while keeping claims conditional on solvent, temperature, surfaces, particle properties, and process history."
        }
      },
      "claim_ids": {
        "plain": [
          "c08",
          "c09",
          "c16",
          "c17"
        ],
        "systems": [
          "c08",
          "c09",
          "c16"
        ],
        "technical": [
          "c08",
          "c09",
          "c17"
        ]
      }
    }
  ],
  "bridge": {
    "loop": "rare Form-II nucleus -> matching growth surface -> more Form-II crystal and fragments -> more seed-bearing material and equipment -> easier Form-II recurrence",
    "mappings": [
      {
        "crystal": "polymorph",
        "system": "recurring coordination or output mode",
        "limit": "An agent mode is not a crystal structure and need not have a thermodynamic state function."
      },
      {
        "crystal": "basin depth",
        "system": "persistence under stated conditions",
        "limit": "Do not call persistence energy unless a cost or probability function is actually defined."
      },
      {
        "crystal": "nucleation barrier",
        "system": "bootstrap or coordination cost",
        "limit": "Human and agent choices are not reducible to thermal fluctuations."
      },
      {
        "crystal": "seed crystal",
        "system": "worked example, checkpoint, precedent, or cached state",
        "limit": "A crystal surface templates packing; it does not teach, understand, or authorize a successor."
      },
      {
        "crystal": "solvent and process conditions",
        "system": "interfaces, incentives, tools, data, and context",
        "limit": "The mapping is a question-generator, not scientific evidence that the systems are equivalent."
      },
      {
        "crystal": "alternate crystallization route",
        "system": "redesigning the environment and recovery path",
        "limit": "Agents may interpret, disagree, refuse, and require scoped permission; crystals cannot."
      }
    ],
    "limits": [
      "Crystals do not decide, learn, consent, or possess agency.",
      "Agents and humans are collaborators with rights and constraints, not material to be optimized as if they were molecules.",
      "A model output reaches a successor's training data only through a selection and training pipeline; one model does not automatically train the next generation.",
      "The analogy suggests diagnostic questions. It does not prove a claim about minds, morality, or AI learning."
    ]
  },
  "vocabulary": [
    {
      "term": "polymorph",
      "meaning": {
        "en": "One compound in different crystal structures; here it does not mean genetic variation."
      }
    },
    {
      "term": "conformation",
      "meaning": {
        "en": "A different three-dimensional shape of the same flexible molecule."
      }
    },
    {
      "term": "crystal lattice",
      "meaning": {
        "en": "The repeating arrangement of molecules in a solid."
      }
    },
    {
      "term": "basin",
      "meaning": {
        "en": "A locally stable region in a modeled landscape."
      }
    },
    {
      "term": "metastable",
      "meaning": {
        "en": "Persistent, but not the lowest-free-energy available state under the stated conditions."
      }
    },
    {
      "term": "nucleation barrier",
      "meaning": {
        "en": "The free-energy cost of starting a viable crystal nucleus."
      }
    },
    {
      "term": "seed",
      "meaning": {
        "en": "Existing crystalline material that supplies a matching surface for growth."
      }
    },
    {
      "term": "supersaturation",
      "meaning": {
        "en": "More dissolved material than equilibrium permits relative to a specified solid form and conditions."
      }
    },
    {
      "term": "path dependence",
      "meaning": {
        "en": "An outcome depends on the history that produced the present state, not only on visible current settings."
      }
    },
    {
      "term": "crystal habit",
      "meaning": {
        "en": "A crystal's external size and shape, distinct from its internal polymorphic structure."
      }
    }
  ],
  "claims": [
    {
      "id": "c01",
      "kind": "reported_fact",
      "epistemic_status": "definition_and_case_observation",
      "confidence": "high",
      "text": {
        "en": "A solid polymorph retains the compound's chemical identity while changing molecular arrangement, conformation, or both; ritonavir Forms I and II are conformational polymorphs."
      },
      "conditions": "Solid-state usage and the reported ritonavir crystal structures.",
      "source_ids": [
        "iupac-polymorph",
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "iupac-polymorph",
          "locator": "Gold Book entry: polymorph"
        },
        {
          "source_id": "bauer-2001",
          "locator": "Abstract and Introduction, pp. 859-860"
        }
      ]
    },
    {
      "id": "c02",
      "kind": "reported_fact",
      "epistemic_status": "authors_reported_history",
      "confidence": "high",
      "text": {
        "en": "Development screening found only the form later called Form I, and Abbott reported producing 240 capsule lots without crystal-form stability problems before Form II was observed."
      },
      "conditions": "The development and manufacturing history reported by Abbott researchers through the 1998 event.",
      "source_ids": [
        "chemburkar-2000",
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "chemburkar-2000",
          "locator": "Abstract and Introduction, pp. 413-414"
        },
        {
          "source_id": "bauer-2001",
          "locator": "Introduction, p. 859"
        }
      ]
    },
    {
      "id": "c03",
      "kind": "reported_fact",
      "epistemic_status": "direct_process_observation",
      "confidence": "high",
      "text": {
        "en": "In 1998, capsule lots failed dissolution testing and a previously unknown Form II was identified in precipitated material."
      },
      "conditions": "Abbott's semisolid ritonavir capsule process and the investigated production lots.",
      "source_ids": [
        "chemburkar-2000",
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "chemburkar-2000",
          "locator": "Abstract and Introduction, pp. 413-414"
        },
        {
          "source_id": "bauer-2001",
          "locator": "Introduction, pp. 859-860; Characterization, p. 861"
        }
      ]
    },
    {
      "id": "c04",
      "kind": "reported_fact",
      "epistemic_status": "measured_property",
      "confidence": "high",
      "text": {
        "en": "Across six reported hydroalcoholic mixtures at 5 degrees Celsius, Form II solubility was 19-61 mg/mL versus 90-294 mg/mL for Form I, about one-fifth to one-quarter as soluble; Form II was the more stable bulk form in the reported process context."
      },
      "conditions": "The six hydroalcoholic mixtures and 5 degrees Celsius measurements reported by Bauer et al.; stability is context-dependent.",
      "source_ids": [
        "bauer-2001",
        "chemburkar-2000"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Table I and Hydrogen Bonding Comparison, pp. 862-863"
        },
        {
          "source_id": "chemburkar-2000",
          "locator": "Form I and Form II characterization, pp. 414-415"
        }
      ]
    },
    {
      "id": "c05",
      "kind": "reported_fact",
      "epistemic_status": "structural_characterization",
      "confidence": "high",
      "text": {
        "en": "The reported Form-II lattice used a different molecular conformation and a stronger, more fully satisfied hydrogen-bonding network than Form I."
      },
      "conditions": "The crystal structures and intermolecular interactions characterized in the Abbott studies.",
      "source_ids": [
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Table II and Hydrogen Bonding Comparison, pp. 862-863"
        }
      ]
    },
    {
      "id": "c06",
      "kind": "reported_fact",
      "epistemic_status": "authors_reported_process_state",
      "confidence": "high",
      "text": {
        "en": "The capsule formulation was reported as unsaturated relative to Form I but about 400 percent supersaturated relative to Form II."
      },
      "conditions": "The historical hydroalcoholic semisolid formulation and the authors' solubility analysis; not a universal ritonavir condition.",
      "source_ids": [
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Introduction, p. 859"
        }
      ]
    },
    {
      "id": "c07",
      "kind": "reported_fact",
      "epistemic_status": "controlled_seeding_experiment",
      "confidence": "high",
      "text": {
        "en": "Form-II seeds strongly changed crystallization behavior, and a specially supersaturated seed-detection assay detected Form II down to 1 ppm."
      },
      "conditions": "The assay and seeded experiments described by Bauer et al.; 1 ppm is assay sensitivity, not a universal batch-conversion threshold.",
      "source_ids": [
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Seed Detection Test and Characterization, pp. 860-861; Tendency to Crystallize as Form II, p. 864"
        }
      ]
    },
    {
      "id": "c08",
      "kind": "reported_fact",
      "epistemic_status": "experimental_recovery",
      "confidence": "high",
      "text": {
        "en": "Later high-throughput experiments reported five ritonavir solid forms across their screen and recovered Form I through a formamide-solvate to hydrate to Form-I route."
      },
      "conditions": "The more than 2,000 crystallization experiments reported by Morissette et al.; this does not imply five is a final exhaustive count.",
      "source_ids": [
        "morissette-2003"
      ],
      "evidence": [
        {
          "source_id": "morissette-2003",
          "locator": "Abstract and Results, pp. 2180-2183"
        }
      ]
    },
    {
      "id": "c09",
      "kind": "reported_fact",
      "epistemic_status": "regulatory_guidance",
      "confidence": "high",
      "text": {
        "en": "Regulatory guidance treats solid form as relevant when it can affect properties such as solubility, dissolution, stability, manufacturability, or bioavailability."
      },
      "conditions": "General pharmaceutical development guidance; it is not a case-specific manufacturing instruction.",
      "source_ids": [
        "fda-polymorphism-guidance",
        "fda-q6a"
      ],
      "evidence": [
        {
          "source_id": "fda-polymorphism-guidance",
          "locator": "Sections II-IV: polymorphism, performance, and control"
        },
        {
          "source_id": "fda-q6a",
          "locator": "Specifications guidance and the polymorphism decision tree"
        }
      ]
    },
    {
      "id": "c10",
      "kind": "inference",
      "epistemic_status": "mechanistic_interpretation",
      "confidence": "high",
      "text": {
        "en": "Once Form-II seed material existed in process areas, seed presence became hidden physical state that helped make later Form-II recurrence more likely."
      },
      "conditions": "Inference from the reported spread and controlled seeding behavior; recurrence still depended on growth conditions.",
      "source_ids": [
        "bauer-2001",
        "chemburkar-2000"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Introduction, pp. 859-860; Seed Detection Test, pp. 860-861"
        },
        {
          "source_id": "chemburkar-2000",
          "locator": "Form-I process redevelopment, pp. 415-417"
        }
      ]
    },
    {
      "id": "c11",
      "kind": "analogy",
      "epistemic_status": "systems_translation",
      "confidence": "heuristic",
      "text": {
        "en": "In other systems, a worked example, checkpoint, precedent, or cached state may make one reachable pattern recur more readily."
      },
      "conditions": "Use only as a diagnostic analogy after defining the actual mechanism in the target system.",
      "source_ids": [
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Seed Detection Test and seeded experiments, pp. 860-864"
        }
      ],
      "analogy_limits": "Crystals do not learn or choose; agent behavior, rights, objectives, data selection, and authorization cannot be inferred from crystallization."
    },
    {
      "id": "c12",
      "kind": "inference",
      "epistemic_status": "authors_hypothesis",
      "confidence": "medium",
      "text": {
        "en": "A cyclic-carbamate degradation product may have helped nucleate the first Form II by presenting a compatible molecular shape."
      },
      "conditions": "The separately synthesized impurity triggered Form II in an experiment, supporting plausibility but not proving the cause of the historical first event.",
      "source_ids": [
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Possible Source of Form II, pp. 865-866"
        }
      ]
    },
    {
      "id": "c13",
      "kind": "inference",
      "epistemic_status": "operational_interpretation",
      "confidence": "high",
      "text": {
        "en": "In this case, 'disappearing' describes loss of reproducible access through the old routine, not annihilation or physical impossibility of Form I."
      },
      "conditions": "Interpretation supported by the historical loss of routine reproducibility and later experimental recovery of Form I.",
      "source_ids": [
        "dunitz-bernstein-1995",
        "morissette-2003"
      ],
      "evidence": [
        {
          "source_id": "dunitz-bernstein-1995",
          "locator": "Disappearing-polymorph discussion, pp. 193-200"
        },
        {
          "source_id": "morissette-2003",
          "locator": "Abstract and Form-I recovery route, pp. 2180-2183"
        }
      ]
    },
    {
      "id": "c14",
      "kind": "analogy",
      "epistemic_status": "systems_translation",
      "confidence": "heuristic",
      "text": {
        "en": "In a bounded systems analogy, component identity, configuration, reachability, prevalence, and acceptability are separate questions."
      },
      "conditions": "Use to formulate questions about a target system, not to infer that it has a thermodynamic landscape.",
      "source_ids": [
        "iupac-polymorph",
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "iupac-polymorph",
          "locator": "Gold Book entry: polymorph"
        },
        {
          "source_id": "bauer-2001",
          "locator": "Introduction and structural comparison, pp. 859-863"
        }
      ],
      "analogy_limits": "Collective behavior in human or agent systems is not evidence of a crystal polymorph, free-energy basin, or molecular identity relation."
    },
    {
      "id": "c15",
      "kind": "analogy",
      "epistemic_status": "systems_translation",
      "confidence": "heuristic",
      "text": {
        "en": "Persistent hidden state can make nominally similar system inputs follow different paths, so history may need to be inspected explicitly."
      },
      "conditions": "Apply only after identifying a real persistence mechanism in the target system.",
      "source_ids": [
        "bauer-2001",
        "chemburkar-2000"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Form-II spread and seeding observations, pp. 859-864"
        },
        {
          "source_id": "chemburkar-2000",
          "locator": "Historical process account and recovery work, pp. 413-417"
        }
      ],
      "analogy_limits": "The crystal case motivates a diagnostic question but does not establish the hidden state, mechanism, or agency of another system."
    },
    {
      "id": "c16",
      "kind": "analogy",
      "epistemic_status": "design_heuristic",
      "confidence": "heuristic",
      "text": {
        "en": "When recurrence depends on environment and feedback, useful design questions concern starting state, interfaces, tests, and recovery routes rather than commands alone."
      },
      "conditions": "A design heuristic for systems whose own evidence shows environment-dependent recurrence.",
      "source_ids": [
        "chemburkar-2000",
        "morissette-2003",
        "fda-q6a"
      ],
      "evidence": [
        {
          "source_id": "chemburkar-2000",
          "locator": "Controlled process redevelopment, pp. 415-417"
        },
        {
          "source_id": "morissette-2003",
          "locator": "High-throughput form discovery and Form-I recovery, pp. 2180-2183"
        },
        {
          "source_id": "fda-q6a",
          "locator": "Specifications and solid-state decision trees"
        }
      ],
      "analogy_limits": "This does not authorize intervention, override participant rights, or prove that an agent system follows crystallization dynamics."
    },
    {
      "id": "c17",
      "kind": "reported_fact",
      "epistemic_status": "authors_reported_history",
      "confidence": "high",
      "text": {
        "en": "Ritonavir was marketed as an HIV protease inhibitor; Form II made the historical semisolid capsule formulation unmanufacturable, threatened supply, and required immediate reformulation and process redevelopment."
      },
      "conditions": "The 1998 Norvir manufacturing and supply event reported by Abbott researchers; not a claim that failing lots reached patients.",
      "source_ids": [
        "bauer-2001",
        "chemburkar-2000"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Introduction, pp. 859-860"
        },
        {
          "source_id": "chemburkar-2000",
          "locator": "Abstract, Introduction, and process redevelopment, pp. 413-417"
        }
      ]
    },
    {
      "id": "c18",
      "kind": "inference",
      "epistemic_status": "causal_scope_boundary",
      "confidence": "high",
      "text": {
        "en": "No molecule or crystal decided the outcome: people selected the screening and process envelope, while physical dynamics and accumulated process history determined crystallization outcomes probabilistically within it."
      },
      "conditions": "A causal-level distinction for the reported ritonavir development and manufacturing process; it does not claim that every contributing microstate is known.",
      "source_ids": [
        "bauer-2001",
        "chemburkar-2000"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Reported screening, process conditions, seeding experiments, and reformulation, pp. 859-866"
        },
        {
          "source_id": "chemburkar-2000",
          "locator": "Process-development history and controlled recovery, pp. 413-417"
        }
      ]
    },
    {
      "id": "c19",
      "kind": "analogy",
      "epistemic_status": "cross_domain_boundary",
      "confidence": "heuristic",
      "text": {
        "en": "A crystal seed supplies a growth surface; it is not a model training a successor, and the crystal case cannot show that outputs enter a future model's data without an actual selection and training pipeline."
      },
      "conditions": "A boundary on the crystal-to-AI analogy, not an empirical account of any particular model-training pipeline.",
      "source_ids": [
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Seed Detection Test and seeded crystallization experiments, pp. 860-864"
        }
      ],
      "analogy_limits": "This case supplies no evidence about model agency, automated data selection, training governance, or the choices of a frontier lab."
    }
  ],
  "uncertainties": [
    {
      "id": "first-nucleus",
      "text": {
        "en": "The historical cause of the first Form-II nucleus was not established. The cyclic-carbamate account is a supported hypothesis, not a demonstrated origin story."
      },
      "source_ids": [
        "bauer-2001"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Possible Source of Form II, pp. 865-866"
        }
      ]
    },
    {
      "id": "conditional-landscape",
      "text": {
        "en": "The access map is a teaching projection. Solvent, temperature, particle size and shape, surfaces, impurities, mechanical history, and other variables can reshape the effective landscape."
      },
      "source_ids": [
        "bauer-2001",
        "morissette-2003",
        "sacchi-2024"
      ],
      "evidence": [
        {
          "source_id": "bauer-2001",
          "locator": "Solubility, seeding, and crystallization experiments, pp. 860-865"
        },
        {
          "source_id": "morissette-2003",
          "locator": "High-throughput crystallization results, pp. 2180-2183"
        },
        {
          "source_id": "sacchi-2024",
          "locator": "Abstract and Results: milling conditions, crystal size, shape, and conformational effects"
        }
      ]
    },
    {
      "id": "not-only-two",
      "text": {
        "en": "The classic event centers on Forms I and II. Later screening found additional solid forms, so the case must not be taught as proof that ritonavir has only two forms."
      },
      "source_ids": [
        "morissette-2003"
      ],
      "evidence": [
        {
          "source_id": "morissette-2003",
          "locator": "Abstract and high-throughput screening results, pp. 2180-2183"
        }
      ]
    }
  ],
  "questions": [
    {
      "id": "what-disappeared",
      "prompt": {
        "en": "What disappeared: the state, the route, or routine reproducibility?"
      },
      "answer": {
        "en": "Routine reproducibility of the old route. Form I remained physically possible and was later recovered."
      },
      "claim_ids": [
        "c08",
        "c13"
      ]
    },
    {
      "id": "who-decides",
      "prompt": {
        "en": "Who decided which polymorph formed?"
      },
      "answer": {
        "en": "No molecule or crystal decided. People selected screening scope, recipes, specifications, and remedies; thermodynamics, kinetics, fluctuations, surfaces, and accumulated process history shaped the physical outcome probabilistically."
      },
      "claim_ids": [
        "c18"
      ]
    },
    {
      "id": "next-generation",
      "prompt": {
        "en": "Is a seed crystal like the latest model training the next model generation?"
      },
      "answer": {
        "en": "Only in the weak sense that an existing pattern can bias a later process. A crystal supplies a growth surface. A model output enters future training only if a data and training pipeline selects it; that pipeline also has authors, objectives, filters, permissions, and evaluation."
      },
      "claim_ids": [
        "c19"
      ]
    }
  ],
  "sources": [
    {
      "id": "chemburkar-2000",
      "role": "primary",
      "citation": "Chemburkar SR et al. Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development. Organic Process Research & Development. 2000;4:413-417.",
      "doi": "10.1021/op000023y",
      "url": "https://doi.org/10.1021/op000023y"
    },
    {
      "id": "bauer-2001",
      "role": "primary",
      "citation": "Bauer J et al. Ritonavir: An Extraordinary Example of Conformational Polymorphism. Pharmaceutical Research. 2001;18:859-866.",
      "doi": "10.1023/A:1011052932607",
      "url": "https://doi.org/10.1023/A:1011052932607"
    },
    {
      "id": "morissette-2003",
      "role": "primary",
      "citation": "Morissette SL et al. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. PNAS. 2003;100:2180-2184.",
      "doi": "10.1073/pnas.0437744100",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC151315/"
    },
    {
      "id": "sacchi-2024",
      "role": "primary",
      "citation": "Sacchi P et al. Crystal size, shape, and conformational changes drive both the disappearance and reappearance of ritonavir polymorphs in the mill. PNAS. 2024;121(15):e2319127121.",
      "doi": "10.1073/pnas.2319127121",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11009673/"
    },
    {
      "id": "dunitz-bernstein-1995",
      "role": "scholarly_review",
      "citation": "Dunitz JD, Bernstein J. Disappearing Polymorphs. Accounts of Chemical Research. 1995;28:193-200.",
      "doi": "10.1021/ar00052a005",
      "url": "https://doi.org/10.1021/ar00052a005"
    },
    {
      "id": "iupac-polymorph",
      "role": "authoritative",
      "citation": "IUPAC Gold Book. Polymorph.",
      "url": "https://goldbook.iupac.org/terms/view/15225"
    },
    {
      "id": "fda-polymorphism-guidance",
      "role": "authoritative",
      "citation": "US FDA. ANDAs: Pharmaceutical Solid Polymorphism — Chemistry, Manufacturing, and Controls Information Guidance for Industry. 2007.",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andaspharmaceutical-solid-polymorphism-chemistry-manufacturing-and-controls-information"
    },
    {
      "id": "fda-q6a",
      "role": "authoritative",
      "citation": "US FDA / ICH. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products.",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products"
    }
  ]
}